Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | FBP1 | P09467 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29508979 | 1.00 | MAPT (0.57) | MAPTFBP1LMNAALDH1A1RECQL | |
| SCHEMBL3039038 | 0.87 | LMNA (0.51) | MAPTFBP1LMNAALDH1A1RECQL | |
| SCHEMBL22897608 | 0.84 | MAPT (0.42) | MAPTFBP1LMNAALDH1A1RECQL | |
| SCHEMBL29212458 | 0.83 | NPC1 (0.42) | MAPTFBP1LMNAALDH1A1RECQL | |
| SCHEMBL23589335 | 0.83 | ALDH1A1 (0.53) | MAPTLMNAALDH1A1MAPK1MEN1 | |
| SCHEMBL15508187 | 0.83 | NPC1 (0.50) | MAPTLMNAALDH1A1RECQLMAPK1 | |
| SCHEMBL10197531 | 0.81 | NPC1 (0.46) | MAPTALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL20577146 | 0.81 | NPC1 (0.45) | MAPTLMNAALDH1A1RECQLKMT2A | |
| SCHEMBL10197528 | 0.81 | NPC1 (0.49) | MAPTALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL11058768 | 0.81 | MAPT (0.58) | MAPTLMNAALDH1A1RECQLMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179059-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-06-05 | — | — | US | disclosed |
| US-12312339-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-12162870-B2 | Anticancer compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240270722-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2024-08-15 | — | — | US | disclosed |
| US-20240124426-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2024-04-18 | — | — | US | disclosed |
| EP-4351560-A1 | ANTICANCER COMPOUNDS | The Regents of the University of California (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-117794529-A | POLO-like kinase 4 inhibitors | 欧瑞克制药公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117794525-A | Anticancer compounds | 加利福尼亚大学董事会 | 2024-03-29 | — | — | CN | disclosed |
| EP-4337198-A1 | POLO LIKE KINASE 4 INHIBITORS | Oric Pharmaceuticals, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20240067648-A1 | N-OXIDE INHIBITORS OF NLRP3 INFLAMMASOME | BioAge Labs, Inc. | 2024-02-29 | — | — | US | disclosed |
| US-20070208054-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-06 | — | — | US | disclosed |
| US-20070208054-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-06 | — | — | US | disclosed |
| US-20070208054-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-06 | — | — | US | disclosed |
| WO-2007076431-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070088067-A1 | Novel amidine compounds for treating microbial infections | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2007-04-19 | — | — | US | disclosed |
| EP-1663959-A1 | NOVEL AMIDINE COMPOUNDS FOR TREATING MICROBIAL INFECTIONS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005033065-A1 | NOVEL AMIDINE COMPOUNDS FOR TREATING MICROBIAL INFECTIONS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2005-04-14 | — | — | WO | disclosed |
| US-6706754-B2 | ANTIPROTOZOA AGENTS, PARASITICIDES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2004-03-16 | — | — | US | disclosed |
| US-20020156098-A1 | Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis | ARMY, UNITED STATES | 2002-10-24 | — | — | US | disclosed |
| WO-2002036588-A2 | REVERSED AMIDINES AND METHODS OF USING FOR TREATING, PREVENTING, OR INHIBITING LEISHMANIASIS | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND (US) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179059-A1 | ANTICANCER COMPOUNDS | BET1, BRD4, BICRA | MAPT 2666/4885FBP1 2236/4885LMNA 4337/4885 |
| US-20240124426-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | MAPT 1102/4885FBP1 1932/4885LMNA 2193/4885 |
| US-20070088067-A1 | Novel amidine compounds for treating microbial infections | ARG1, ARG2, GSDMD | MAPT 2490/4885FBP1 1786/4885LMNA 4384/4885 |
| US-12312339-B2 | Polo like kinase 4 inhibitors | PLK4, PLK2, PLK3 | MAPT 1102/4885FBP1 1932/4885LMNA 2193/4885 |
| US-20070208054-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | F12, F7, F2 | MAPT 1936/4885FBP1 667/4885LMNA 217/4885 |
| US-20240067648-A1 | N-OXIDE INHIBITORS OF NLRP3 INFLAMMASOME | NLRP3, NOD1, CASP1 | MAPT 940/4885FBP1 3339/4885LMNA 407/4885 |
| US-20020156098-A1 | Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis | ARG1, NAT1, CTSA | MAPT 4882/4885FBP1 2158/4885LMNA 515/4885 |
| US-20240270722-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | MAPT 1151/4885FBP1 1817/4885LMNA 2199/4885 |
| US-12162870-B2 | Anticancer compounds | BET1, BRD4, BICRA | MAPT 2666/4885FBP1 2236/4885LMNA 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.